What is TERN's current stock price?

TERN (Terns Pharmaceuticals, Inc.) is currently trading at $52.95 with a market cap of $4.77B.

What sector is Terns Pharmaceuticals, Inc. in?

Terns Pharmaceuticals, Inc. (TERN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TERN a good stock to buy?

Analysts have a Hold consensus on TERN with a price target of $55.56. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TERN Terns Pharmaceuticals, Inc.

Healthcare

$52.95-0.03%ClosedMarket Cap: $4.77B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.90

P/S

0.00

EV/EBITDA

-38.55

DCF Value

$5.60

FCF Yield

-1.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-20.0%

ROA

-9.4%

ROIC

-10.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$0.00	$-23.6M	$—
FY null	$0.00	$-96.2M	$—
Q3 null	$0.00	$-24.6M	$—
Q2 null	$0.00	$-24.1M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$55.56

Target (Median)

$56.00

Target Range

$35.00 - $70.00

0 Strong Buy0 Buy10 Hold0 Sell0 Strong Sell

OppenheimerPerform

2026-04-27

JP MorganOverweight

2026-04-14

Truist SecuritiesHold

2026-03-31

BarclaysEqual Weight

2026-03-30

CitizensMarket Perform

2026-03-26

Trading Activity

Insider Trades

View All

Turner Heather Ddirector

SellTue May 05

Turner Heather Ddirector

SellTue May 05

Turner Heather Ddirector

SellTue May 05

Tripuraneni Radhikadirector

SellTue May 05

Tripuraneni Radhikadirector

SellTue May 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.38

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Peers